Merck said on Tuesday a study showed its injectable version of cancer drug Keytruda was not inferior to the currently ...

Merck's new formulation could help secure a larger share of Keytruda's sales after the cancer drug's U.S. patent expires in ...

Merck (NYSE:MRK) announced Tuesday that a subcutaneously delivered version of its blockbuster cancer therapy pembrolizumab ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the ...

Merck & Co.’ Inc.’s stock MRK rose 2% premarket Tuesday, after the company reported positive results for a new formulation of its blockbuster cancer drug Keytruda. Rahway, N.J.-based Merck said a ...

The ongoing trial is assessing the drug's performance both as a standalone therapy and in combination with the programmed cell death protein 1 (PD-1) checkpoint inhibitor Keytruda. It is structured as ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

Germany-based BioNTech got into the space before the gold rush that was unleashed in September by the news that Akeso and ...

The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...

Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug ...